Abstract: The present invention provides a lipid membrane that contains a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22. Use of the present invention enables screening for a chemical which regulates excretion of a chemical and/or a waste. Furthermore, use of the present invention enables an arbitrary chemical to be tested for nephrotoxicity and/or hepatotoxicity.
Abstract: The present invention provides a lipid membrane that contains a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22. Use of the present invention enables screening for a chemical which regulates excretion of a chemical and/or a waste. Furthermore, use of the present invention enables an arbitrary chemical to be tested for nephrotoxicity and/or hepatotoxicity.
Abstract: The present invention provides a lipid membrane that contains a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22. Use of the present invention enables screening for a chemical which regulates excretion of a chemical and/or a waste. Furthermore, use of the present invention enables an arbitrary chemical to be tested for nephrotoxicity and/or hepatotoxicity.
Abstract: The present invention provides a lipid membrane that contains a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22. Use of the present invention enables screening for a chemical which regulates excretion of a chemical and/or a waste. Furthermore, use of the present invention enables an arbitrary chemical to be tested for nephrotoxicity and/or hepatotoxicity.
Abstract: The present invention is a method for screening a remedy for breast cancer which does not require uptake into cells unlike aromatase inhibitors, estrogen sulfatase inhibitors, or estrogen competitive inhibitors such as tamoxifen and toremifene, and which shows excellent drug delivery property and extremely rare adverse effect. In the method, a remedy for breast cancer which inhibits transporter function is screened by the process comprising the steps of: culturing a cultured human breast cancer cell line such as MCF-7 cell line or T-47D cell line in the presence of estrone-3-sulfate and a test substance such as bromosulfophtalein; and evaluating whether the uptake of estrone-3-sulfate into cells via estrone-3-sulfate transporters expressed on the cell surface is inhibited, and whether the proliferation of MCF-7 cell line is suppressed.